AI Verdict
REGN has stronger fundamentals based on our AI analysis.
COR vs REGN Fundamental Comparison
| Metric | COR | REGN |
|---|---|---|
| Revenue | $85.9B | $14.3B |
| Net Income | $559.6M | $4.5B |
| Net Margin | 0.7% | 31.4% |
| ROE | 29.3% | 14.4% |
| ROA | 0.7% | 11.1% |
| Current Ratio | 0.92x | 4.13x |
| Debt/Equity | 4.15x | 0.06x |
| EPS | $2.87 | $41.48 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
COR vs REGN: Frequently Asked Questions
Is COR or REGN a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), REGN has stronger fundamentals. COR is rated SELL (74% confidence) while REGN is rated BUY (80% confidence). This is not investment advice.
How does COR compare to REGN fundamentally?
Cencora, Inc. has ROE of 29.3% vs REGENERON PHARMACEUTICALS, INC.'s 14.4%. Net margins are 0.7% vs 31.4% respectively.
Which stock pays higher dividends, COR or REGN?
COR has a dividend yield of N/A or no dividend while REGN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in COR or REGN for long term?
For long-term investing, consider that COR has SELL rating with 74% confidence, while REGN has BUY rating with 80% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about COR vs REGN?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For COR vs REGN, the AI consensus favors REGN based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.